Startup profile · funding coverage
Suki funding, valuation and investors
Healthcare AI platform expanding from ambient documentation into clinical, financial and operational workflows.
Keep track of Suki
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series E
$90 million · October 13, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$90M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Redwood City, California, United States
Investors in latest funding
Lead: Healthier Capital
Other: Crosslink Capital , Hercules Capital , Venrock , Flare Capital Partners , Hedosophia , Philips Ventures , Zoom Ventures
Overview
Redwood City-based Suki provides ambient clinical intelligence through a clinician-facing application and embedded partnerships with health-technology vendors.
Why Suki is interesting
Suki is using ambient documentation as an entry point into a broader healthcare AI operating layer, with more than 450 healthcare organizations and over 30 technology partners reported by the company.
Product & use cases
Suki converts clinical conversations into documentation and supports coding, revenue-cycle, clinical-reasoning and operational workflows. It sells directly to clinicians and health systems while licensing capabilities through embedded technology partners.
- Ambient clinical documentation
- Clinical reasoning assistance
- Coding and revenue-cycle workflows
- Embedded healthcare AI
Key facts
- $90 million Series E announced October 13, 2026.
- More than 450 healthcare organizations and 30 technology partners, according to the company.
- Patient encounters supported grew more than 190% year over year in 2026, according to Suki.
Funding history (newest first)
Series E
2026-10-13 $90 million- Healthier Capital (lead)
- Crosslink Capital (participant)
- Hercules Capital (participant)
- Venrock (participant)
- Flare Capital Partners (participant)
- Hedosophia (participant)
- Philips Ventures (participant)
- Zoom Ventures (participant)
Investors in our directory
Funds linked from Suki's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: A dual distribution model combines a clinician-facing application with embedded partnerships, potentially giving Suki workflow reach that single-point ambient scribe products lack.
Suki competes with ambient clinical intelligence and documentation providers including Abridge, Ambience Healthcare, Microsoft/Nuance and health-system-native AI tools. The core test is whether its broader workflow layer can improve measurable clinical and financial outcomes without adding another fragmented point solution.
-
Abridge direct
Ambient clinical documentation and enterprise healthcare AI competitor.
-
Ambience Healthcare direct
Competes in ambient documentation and broader clinical workflows.
-
Microsoft Nuance incumbent
Incumbent clinical speech and documentation platform.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Suki's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.